研究报告 |
|
|
|
|
FGFR3基因突变影响膀胱癌酪氨酸激酶抑制剂敏感性的研究* |
邓李歆旭1,2,车文安1,2,徐海波2,丁雪1,孙远东1,**() |
1 湖南科技大学 湘潭 411201 2 深圳市第二人民医院医学合成生物学临床应用关键技术国家地方联合工程实验室 深圳 518036 |
|
Effect of FGFR3 Gene Mutation on Tyrosine Kinase Inhibitor Sensitivity in Bladder Cancer |
DENG Lixinxu1,2,CHE Wenan1,2,XU Haibo2,DING Xue1,SUN Yuandong1,**() |
1 Hunan University of Science and Technology, Xiangtan 411201, China 2 State and Local Government Joint Engineering Laboratory of Synthetic Biology Medicine and Clinical Application of Key Technologies, Shenzhen Second People’s Hospital, Shenzhen 518036, China |
引用本文:
邓李歆旭, 车文安, 徐海波, 丁雪, 孙远东. FGFR3基因突变影响膀胱癌酪氨酸激酶抑制剂敏感性的研究*[J]. 中国生物工程杂志, 2024, 44(2/3): 1-13.
DENG Lixinxu, CHE Wenan, XU Haibo, DING Xue, SUN Yuandong. Effect of FGFR3 Gene Mutation on Tyrosine Kinase Inhibitor Sensitivity in Bladder Cancer. China Biotechnology, 2024, 44(2/3): 1-13.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.2306001
或
https://manu60.magtech.com.cn/biotech/CN/Y2024/V44/I2/3/1
|
[1] |
Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians, 2021, 71(3): 209-249.
doi: 10.3322/caac.v71.3
|
[2] |
Sanli O, Dobruch J, Knowles M A, et al. Bladder cancer. Nature Reviews Disease Primers, 2017, 3: 17022.
doi: 10.1038/nrdp.2017.22
pmid: 28406148
|
[3] |
De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol, 2012, 30: 191.
doi: 10.1200/JCO.2011.37.3571
pmid: 22162575
|
[4] |
Scholtes M P, Alberts A R, Iflé I G, et al. Biomarker-oriented therapy in bladder and renal cancer. International Journal of Molecular Sciences, 2021, 22(6): 2832.
|
[5] |
Wu Y M, Su F Y, Kalyana-Sundaram S, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discovery, 2013, 3(6): 636-647.
doi: 10.1158/2159-8290.CD-13-0050
|
[6] |
Nakanishi Y, Akiyama N, Tsukaguchi T, et al. Mechanism of oncogenic signal activation by the novel fusion kinase FGFR3-BAIAP2L1. Molecular Cancer Therapeutics, 2015, 14(3): 704-712.
doi: 10.1158/1535-7163.MCT-14-0927-T
pmid: 25589496
|
[7] |
Shi M J, Meng X Y, Lamy P, et al. APOBEC-mediated mutagenesis as a likely cause of FGFR3 S249C mutation over-representation in bladder cancer. European Urology, 2019, 76(1): 9-13.
doi: 10.1016/j.eururo.2019.03.032
|
[8] |
Tomlinson D C, Baldo O, Harnden P, et al. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. The Journal of Pathology, 2007, 213(1): 91-98.
doi: 10.1002/path.v213:1
|
[9] |
Williams S V, Hurst C D, Knowles M A. Oncogenic FGFR3 gene fusions in bladder cancer. Human Molecular Genetics, 2013, 22(4): 795-803.
doi: 10.1093/hmg/dds486
pmid: 23175443
|
[10] |
Drost J, Clevers H. Translational applications of adult stem cell-derived organoids. Development, 2017, 144(6): 968-975.
doi: 10.1242/dev.140566
pmid: 28292843
|
[11] |
Pauli C, Hopkins B D, Prandi D, et al. Personalized in vitro and in vivo cancer models to guide precision medicine. Cancer Discovery, 2017, 7(5): 462-477.
doi: 10.1158/2159-8290.CD-16-1154
|
[12] |
Fatehullah A, Tan S H, Barker N. Organoids as an in vitro model of human development and disease. Nature Cell Biology, 2016, 18(3):246-254.
doi: 10.1038/ncb3312
pmid: 26911908
|
[13] |
Medle B, Sjdahl G, Eriksson P, et al. Patient-derived bladder cancer organoid models in tumor biology and drug testing: A systematic review. Cancers, 2022, 14(9):10.3390.
doi: 10.3390/cancers14010010
|
[14] |
Yu L, Li Z C, Mei H B, et al. Patient-derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR-T cells in vitro. Clinical & Translational Immunology, 2021, 10(2): e1248.
|
[15] |
Li Z C, Qian Y H, Li W J, et al. Human lung adenocarcinoma-derived organoid models for drug screening. iScience, 2020, 23(8): 101411.
|
[16] |
Chandrani P, Prabhash K, Prasad R, et al. Drug-sensitive FGFR3 mutations in lung adenocarcinoma. Annals of Oncology, 2017, 28(3): 597-603.
doi: 10.1093/annonc/mdw636
pmid: 27998968
|
[17] |
Lee S H, Hu W H, Matulay J T, et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell, 2018, 173(2): 515-528.e17.
doi: S0092-8674(18)30297-6
pmid: 29625057
|
[18] |
Harada K, Sakamoto N, Ukai S, et al. Establishment of oxaliplatin-resistant gastric cancer organoids: importance of myoferlin in the acquisition of oxaliplatin resistance. Gastric Cancer, 2021, 24(6): 1264-1277.
doi: 10.1007/s10120-021-01206-4
pmid: 34272617
|
[19] |
Ukai S, Honma R, Sakamoto N, et al. Molecular biological analysis of 5-FU-resistant gastric cancer organoids; KHDRBS 3 contributes to the attainment of features of cancer stem cell. Oncogene, 2020, 39: 7265-7278.
doi: 10.1038/s41388-020-01492-9
|
[20] |
Chell V, Balmanno K, Little A S, et al. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance. Oncogene, 2013, 32(25): 3059-3070.
doi: 10.1038/onc.2012.319
pmid: 22869148
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|